New Survey Finds Chatbots Are Still Falling Short of Consumer Expectations
1.2.2023 19:00:00 EET | Business Wire | Press release
Today, Cyara, provider of the award-winning Automated Customer Experience (CX) Assurance Platform, released a new global study that shows while most customers want to use chatbots for automated support, many businesses fail to deliver positive chatbot experiences even as they increasingly rely on them as primary methods of customer interactions online. Additionally, more than half of customers believe a positive or negative chatbot experience is a reflection of the overall brand.
The commissioned survey, conducted in November 2022 by Forrester Consulting on behalf of Cyara, explores the consumer sentiment about chatbots. The study polled 1,554 global consumers who have used sales and/or support chatbots in the last six months about their recent chatbot experiences and expectations.
For most respondents, chatbots were the top way consumers typically interacted with brands in the last six months. Chatbots are particularly popular with UK consumers, with 72% of UK respondents having typically interacted with a brand via chatbot in the last 6 months. However, the global consumers surveyed gave their chatbot experiences an average rating of 6.4/10 or 64%. When specifically asked about their chatbot interactions, 50% of global customers said they often feel frustrated; nearly 40% of these interactions were said to be negative.
Overall, findings from the study include:
-
Customers want to use chatbots. Customers like chatbots as they provide 24/7 support, faster response times, and autonomy. Efficiency is key for UK consumers, with 77% stating the most important aspect of a chatbot interaction is getting their questions answered quickly. The customers that have used chatbots in the last six months rank them higher than speaking directly with an agent or any other digital avenue. However, customers are often met with friction while interacting with them.
-
Almost 75% of global customers agree that chatbots aren’t able to handle complex questions. Customers find chatbots are often unable to provide accurate answers, with more than half of customers agreeing it is difficult to find a solution to their question or problem using a chatbot. Almost half of respondents said that chatbots have provided them with responses and/or solutions that didn’t make sense in the context of their question. Customers also struggle to find alternate resolutions to their problems with more than half of them reporting that they are often unable to connect with an agent even after exhausting the chatbot’s responses.
-
Negative chatbot interactions lead to unfavourable business outcomes. The challenges of using chatbots push customers to seek out alternate and possibly more expensive ways of interacting with a brand. Thirty percent of global customers said after a negative chatbot experience, they are likely to take their purchase to a different brand, abandon their purchase altogether, or tell their friends and family about their poor experience with the brand. And the majority (73%) of UK consumers said they were likely to abandon their purchase after a negative chatbot experience.
- Positive chatbot experiences bring value to customers and businesses. Following good chatbot experiences, 61% of the global customers surveyed said they are more likely to return to a brand. While 56% of global respondents are more likely to seek out chatbots in the future after a positive experience with a chatbot, they are also far more likely to recommend that brand to others afterward.
“Delivering positive chatbot experiences has a critical impact on customer satisfaction and sales, and sub-par chatbots will not cut it for consumers today. Organisations that invest in quality assurance testing and training chatbots can provide customers with better and more consistent chatbot experiences,” said Dennis Reno, Chief Customer Officer of Cyara. “Businesses that strive to meet customers’ chatbot expectations can increase customer loyalty, boost brand reputation, and lower contact centre support costs since customers are less likely to seek out more expensive avenues of communication. And of course, satisfied customers lead to increased sales, which has a positive impact on a company’s bottom line.”
To access the full survey study, visit here.
Survey Methodology
This Forrester Opportunity Snapshot was commissioned by Cyara. To create this study, Forrester Consulting supplemented this research with custom survey questions asked of global consumers who have used sales and/or support chatbots in the last six months. The customer survey began and was completed in November 2022. Respondents were split across the U.S., U.K. (419 respondents), Ireland, Australia and New Zealand and consisted of Baby Boomers, Gen X, Millennials and Gen Z.
About Cyara
Cyara is the world’s leading Automated Customer Experience (CX) Assurance platform, headquartered in Silicon Valley. Cyara’s cloud-based omnichannel assurance solutions for voice quality and chatbot testing accelerate the delivery of flawless customer journeys for enterprises while reducing the risk of customer-facing defects. With a customer retention rate of 96% and a NPS score of 67, every day, major global brands trust the Cyara Platform to deliver customer smiles at scale. For more information, please visit cyara.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230201005218/en/
Contact information
Adele Fairclough / Jacqueline Booker
Cyara@ElevenHundredAgency.com
T: +44(0)20 7688 5202
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
